Tag: medicines

Forbion announces the promotions of Jon Edwards, PhD, to General Partner, Regina Salvat, PhD, to Partner, and John McDonald, MBA, as Operating Partner.

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

Cosmos Health launches Oliv18™, a USDA and EU certified whole olive polyphenol supplement targeting cardiovascular and antioxidant categories.

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

Patients Can Now Connect with Licensed Clinicians through the Informed Pain Care Platform to Receive Timely Evaluation and Access to Non-Opioid Treatment Options for...

SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and...

SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and...

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels

SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the...

Free Gelato + Exclusive Fan Support Hand Fan, Stay Cool. Stay "TO". One Receipt, Triple Summer Rewards: Win The Herbalgy Trophy Tickets!HONG KONG, June 5, 2026...

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...